| 魏凯敏,胡玲.程序性细胞死亡蛋白配体 -1与程序性细胞死亡蛋白配体 -1抑制剂在垂体腺瘤中的研究进展[J].安徽医药,2024,28(5):874-878. |
| 程序性细胞死亡蛋白配体 -1与程序性细胞死亡蛋白配体 -1抑制剂在垂体腺瘤中的研究进展 |
| Research progress on PD-L1 and PD-L1 inhibitors in pituitary adenomas |
| |
| DOI：10.3969/j.issn.1009-6469.2024.05.006 |
| 中文关键词: 程序性死亡［蛋白］配体 -1 垂体腺瘤 侵袭性 |
| 英文关键词: Programmed cell death 1 ligand 1 Pituitary adenoma |
| 基金项目: |
|
| 摘要点击次数: 1761 |
| 全文下载次数: 875 |
| 中文摘要: |
| 垂体腺瘤是垂体最常见的疾病，侵袭性垂体腺瘤和垂体癌对常规诊疗方式效果欠佳，是目前临床治疗的难点。免疫检查点抑制剂是肿瘤免疫治疗新的选择，在垂体腺瘤中的应用受到关注。程序性细胞死亡蛋白配体 -1(PD-L1)/程序性死亡蛋白配体 -1抑制剂目前研究得较为广泛，现重点阐述 PD-L1/PD-L1抑制剂在侵袭性垂体腺瘤中的最新研究进展，以期为临床相关治疗提供参考。 |
| 英文摘要: |
| Pituitary adenoma is the most common disease of pituitary gland. Invasive pituitary adenoma and pituitary carcinoma aredifficult to be diagnosed and treated by conventional methods. Immune checkpoint inhibitors are a new option for tumor immunothera-py, whose application in the treatment of pituitary adenomas has attracted much attention, and programmed cell death protein ligand 1(PD-L1) and PD-L1 inhibitors have been extensively studied. This review focuses on the latest research progress on PD-L1/PD-L1 in-hibitors in invasive pituitary adenomas, in order to provide reference for related clinical treatment. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
